ARMPNot HalalF
Unlock full report, free
Armata Pharmaceuticals, Inc.

ARMP: Is Armata Pharmaceuticals, Inc. Halal?

Armata Pharmaceuticals, Inc.

AMEXHealthcareUS

$3.74

Market Cap: 137.3M

Compliance Status

Not Halal

Screened on Sep 23, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Armata Pharmaceuticals, Inc. (ARMP) halal? Not Halal. Based on AAOIFI screening, Armata Pharmaceuticals, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Armata Pharmaceuticals, Inc. (ARMP) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 23, 2026. Source: https://halalscreener.app/en/stock/ARMP

Business activity

What the company sells is permissible.

Passed

Company debt

Over the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

234.9% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding ARMP

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Get an email if ARMP's halal status changes

We re-screen Armata Pharmaceuticals, Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Interest-bearing debt is 234.9% of market cap, over the 30% AAOIFI limit.
  • Income from prohibited sources is over the 5% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 23, 2026

See which ratio caused the failure.

See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.

Free for 7 days. Cancel anytime.

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

See why ARMP is rated Not Halal with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: FMP
Free · No credit card required

Track ARMP and 8,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Armata Pharmaceuticals, Inc. (ARMP) halal to invest in?
Armata Pharmaceuticals, Inc. (ARMP) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Armata Pharmaceuticals, Inc. get a F compliance rating?
Armata Pharmaceuticals, Inc. (ARMP) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 234.9% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Armata Pharmaceuticals, Inc.'s Shariah verdict?
Armata Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Armata Pharmaceuticals, Inc. re-screened for Shariah compliance?
Armata Pharmaceuticals, Inc. (ARMP) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 23, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.